The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Fampridine Accord fampridine Generic | Accord Healthcare S.L.U. | Multiple Sclerosis | 🇪🇺 EU 2020-09-24 | Order → |
| Jyseleca filgotinib | Alfasigma S.p.A. | Arthritis, Rheumatoid | 🇪🇺 EU 2020-09-24 | Order → |
| Zynrelef bupivacaine;meloxicam | Heron Therapeutics, B.V. | Pain, Postoperative | 🇪🇺 EU 2020-09-24 | Order → |
| Arsenic trioxide medac arsenic trioxide Generic | medac Gesellschaft für klinische Spezialpräparate mbH | Leukemia, Promyelocytic, Acute | 🇪🇺 EU 2020-09-17 | Order → |
| Cabazitaxel Accord cabazitaxel Generic | Accord Healthcare S.L.U. | Prostatic Neoplasms, Castration-Resistant | 🇪🇺 EU 2020-08-28 | Order → |
| Livogiva teriparatide Biosimilar | Theramex Ireland Limited | Osteoporosis | 🇪🇺 EU 2020-08-27 | Order → |
| Qutavina teriparatide Biosimilar | EuroGenerics Holdings B.V. | Osteoporosis | 🇪🇺 EU 2020-08-27 | Order → |
| Blenrep belantamab mafodotin OrphanPRIMEConditional | GlaxoSmithKline Trading Services Limited | Multiple Myeloma | 🇪🇺 EU 2020-08-25 | Order → |
| Idefirix imlifidase OrphanPRIMEConditional | SERB SA | Desensitization, Immunologic; Kidney Transplantation | 🇪🇺 EU 2020-08-25 | Order → |
| Kaftrio ivacaftor;tezacaftor;elexacaftor Orphan | Vertex Pharmaceuticals (Ireland) Limited | Cystic Fibrosis | 🇪🇺 EU 2020-08-21 | Order → |
| Aybintio bevacizumab Biosimilar | Samsung Bioepis NL B.V. | Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell | 🇪🇺 EU 2020-08-19 | Order → |
| Gencebok caffeine citrate | Gennisium Pharma | Apnea | 🇪🇺 EU 2020-08-19 | Order → |
| Lumeblue (previously Methylthioninium chloride Cosmo) methylthioninium chloride | Cosmo Technologies Ltd | Colorectal Neoplasms; Colonoscopy | 🇪🇺 EU 2020-08-19 | Order → |
| Dovprela (previously Pretomanid FGK) pretomanid OrphanAdditional monitoring | Viatris Healthcare Limited | Tuberculosis, Multidrug-Resistant | 🇪🇺 EU 2020-07-31 | Order → |
| Hepcludex bulevirtide OrphanPRIMEAdditional monitoring | Gilead Sciences Ireland UC | Hepatitis D, Chronic | 🇪🇺 EU 2020-07-31 | Order → |
| Rozlytrek entrectinib PRIMEConditionalAdditional monitoring | Roche Registration GmbH | Cancer; Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2020-07-31 | Order → |
| Piqray alpelisib | Novartis Europharm Limited | Breast Neoplasms | 🇪🇺 EU 2020-07-27 | Order → |
| Xenleta lefamulin | Venipharm | Pneumonia, Bacterial; Community-Acquired Infections | 🇪🇺 EU 2020-07-27 | Order → |
| Zercepac trastuzumab BiosimilarAdditional monitoring | Accord Healthcare S.L.U. | Breast Neoplasms; Stomach Neoplasms | 🇪🇺 EU 2020-07-27 | Order → |
| Apixaban Accord apixaban Generic | Accord Healthcare S.L.U. | Venous Thromboembolism; Stroke; Arthroplasty | 🇪🇺 EU 2020-07-23 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.